Trials / Terminated
TerminatedNCT00084240
Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia
A Phase 2/3, Randomized, Comparative, Double Blind Trial Of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to confirm the hypothesis that azithromycin (optimal dose once daily for three days) plus chloroquine is non-inferior to sulfadoxine-pyrimethamine plus chloroquine for the treatment of uncomplicated, symptomatic malaria due to P. falciparum.
Detailed description
The trial was terminated prematurely 2 June 2005 due to the inability to recruit the planned number of subjects. There were no safety or efficacy concerns regarding the study in the decision to terminate the trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Azithromycin/Chloroquine | |
| DRUG | Sulfadoxine-Pyrimethamine/Chloroquine |
Timeline
- Start date
- 2004-03-01
- Completion
- 2005-04-01
- First posted
- 2004-06-11
- Last updated
- 2008-11-03
Source: ClinicalTrials.gov record NCT00084240. Inclusion in this directory is not an endorsement.